Cargando…
Sintilimab induced diabetic ketoacidosis in a patient with small cell lung cancer: A case report and literature review
RATIONALE: Sintilimab is a novel programmed cell death receptor-1 (PD-1) inhibitor approved in the treatment of classical Hodgkin's lymphoma and undergoing clinical trials for various malignancies. As a PD-1 inhibitor, sintilimab is known to cause autoimmune adverse events similar to other PD-1...
Autores principales: | Huang, Xiaofei, Yang, Mei, Wang, Liu, Li, Libo, Zhong, Xiaowei |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8133135/ https://www.ncbi.nlm.nih.gov/pubmed/34106616 http://dx.doi.org/10.1097/MD.0000000000025795 |
Ejemplares similares
-
Sintilimab-related diabetes mellitus and psoriasis: A case report and literature review
por: Huang, Wenying, et al.
Publicado: (2023) -
Tacrolimus-induced diabetic ketoacidosis with subsequent rapid recovery of endogenous insulin secretion after cessation of tacrolimus: A case report with review of literature
por: Maruyama, Koji, et al.
Publicado: (2019) -
Non-diabetic ketoacidosis secondary to primary hyperthyroidism: A case report
por: Al-Mashdali, Abdulrahman F., et al.
Publicado: (2022) -
Case report of severe hypoglycemic alcoholic ketoacidosis: A possible pitfall in diagnosis of ketoacidosis
por: Okauchi, Seizo, et al.
Publicado: (2022) -
An unusual presentation of diabetic ketoacidosis associated with ascariasis and fungal esophagitis: A case report
por: Alduraibi, Rabia Khalid, et al.
Publicado: (2022)